

QUICK REFERENCE DOSING GUIDE  
for CREON 24,000



Click here for CREON 36,000

Per-Meal Dosing Guide

For adult weight-based dosing, perform the CREON DOSING CHECK\*1:

### WEIGHT

- CREON should be initiated at the lowest recommended dose based on the patient's weight
- Weight-based dosing should be used for children ≥4 years and adults

### PLATE

- CREON should be taken with every meal and snack

### TITRATE

- The CREON dosage should be individualized and adjusted based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet



Sample script for a patient who weighs 160 lb.

\* The Cystic Fibrosis Foundation guidelines also provide a dietary fat-based maximum lipase dose of less than 4,000 lipase units per gram of fat ingested per day.

PER MEAL DOSING: Weight-based dosing guide  
for patients prescribed 24,000 lipase unit capsules<sup>1</sup>



	MIN PER MEAL DOSE		MAX PER MEAL DOSE	
80 lbs		24,000 LIPASE UNITS		72,000 LIPASE UNITS
100 lbs		24,000 LIPASE UNITS		96,000 LIPASE UNITS
120 lbs		48,000 LIPASE UNITS		120,000 LIPASE UNITS
140 lbs		48,000 LIPASE UNITS		144,000 LIPASE UNITS
160 lbs		48,000 LIPASE UNITS		168,000 LIPASE UNITS

This chart is intended to be a guide. CREON capsules represent nearest capsule count within recommended dosing range. CREON 24,000 may not be appropriate for all patients. 3,000, 6,000, 12,000, and 36,000 lipase unit capsules are also available.<sup>1</sup> Capsules shown are not actual size and do not represent exact color shade. For illustrative purposes only.

INDICATIONS<sup>1</sup>

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

IMPORTANT SAFETY INFORMATION<sup>1</sup>

- Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
- To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
- Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
- There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
- Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
- Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
- Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
- CREON is not interchangeable with any other pancrelipase product.

Please [click here](#) for full Prescribing Information, including Medication Guide.

References:

1. CREON [package insert]. North Chicago, IL: AbbVie Inc.
2. IMS Health, IMS National Prescription Audit, June 2017.





QUICK REFERENCE DOSING GUIDE  
for CREON 36,000



Click here for CREON 24,000

Per-Meal Dosing Guide

For adult weight-based dosing, perform the CREON DOSING CHECK\*1:

**WEIGHT**

- CREON should be initiated at the lowest recommended dose based on the patient's weight
- Weight-based dosing should be used for children ≥4 years and adults

**PLATE**

- CREON should be taken with every meal and snack

**TITRATE**

- The CREON dosage should be individualized and adjusted based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet



Sample script for a patient who weighs 160 lb.

\* The Cystic Fibrosis Foundation guidelines also provide a dietary fat-based maximum lipase dose of less than 4,000 lipase units per gram of fat ingested per day.

PER MEAL DOSING: Weight-based dosing guide  
for patients prescribed 36,000 lipase unit capsules<sup>1</sup>



	MIN PER MEAL DOSE		MAX PER MEAL DOSE	
110 lbs		36,000 LIPASE UNITS		108,000 LIPASE UNITS
130 lbs		36,000 LIPASE UNITS		144,000 LIPASE UNITS
160 lbs		72,000 LIPASE UNITS		180,000 LIPASE UNITS
200 lbs		72,000 LIPASE UNITS		216,000 LIPASE UNITS
230 lbs		72,000 LIPASE UNITS		252,000 LIPASE UNITS

This chart is intended to be a guide. CREON capsules represent nearest capsule count within recommended dosing range. CREON 24,000 may not be appropriate for all patients. 3,000, 6,000, 12,000, and 24,000 lipase unit capsules are also available.<sup>1</sup> Capsules shown are not actual size and do not represent exact color shade. For illustrative purposes only.

INDICATIONS<sup>1</sup>

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

IMPORTANT SAFETY INFORMATION<sup>1</sup>

- Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
- To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
- Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
- There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
- Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
- Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
- Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
- CREON is not interchangeable with any other pancrelipase product.

Please [click here](#) for full Prescribing Information, including Medication Guide.

References:

1. CREON [package insert]. North Chicago, IL: AbbVie Inc.
2. IMS Health, IMS National Prescription Audit, June 2017.

